Syndication
The exemption from registration is not an exemption from fraud
Every private placement, however perfectly papered, is fully exposed to the anti-fraud rules. Because anti-fraud reaches omissions and survives every exemption, robust risk disclosure is the sponsor's best defense, not a sales liability.
Everything else in this section is about qualifying for an exemption from registration. This page is about the thing no exemption touches. There is no exemption from fraud. A Rule 506 offering is exempt from registering with the SEC; it is not exempt, not even slightly, from the anti-fraud rules. The most carefully papered private placement in the country is fully exposed to them, and the sponsor who thinks the exemption is the finish line has missed the rule that actually generates most private-placement lawsuits.
An exemption exempts you from registration. It never exempts you from telling the truth.
What the anti-fraud rules reach
Several provisions overlap here. Confirm each against the primary source at draft, but the shape is this. Rule 10b-5, under Section 10(b) of the Exchange Act, makes it unlawful, in connection with the purchase or sale of any security, to state a material untruth or to omit a material fact needed to keep what you did say from being misleading. It requires scienter, meaning intent or recklessness. Section 17(a) of the Securities Act reaches fraud in the offer or sale, and some of its prongs reach mere negligence, a lower bar than 10b-5. Section 12(a)(2) adds liability for material misstatements and omissions in certain offering communications. Together they cover the entire arc of talking an investor into a deal.
Two features make them powerful against sponsors. First, they apply to any security, which includes every exempt private placement, so there is no structure that escapes them. Second, they reach omissions, not just affirmative lies. Leaving out something a reasonable investor would consider important is actionable even if every sentence the sponsor actually spoke was true. Materiality is the test: a fact is material if a reasonable investor would consider it important to the decision. The enforcement paths are broad too, private lawsuits by investors, SEC civil enforcement, and in serious cases criminal prosecution.
The counterintuitive consequence
Here is where sponsors get the incentive exactly backwards. The instinct, writing a deal, is to minimize the scary language, soften the risk factors, and keep the story clean, because grim disclosure feels like it will cost the raise. Under anti-fraud law, that instinct is the danger, and the opposite move is the defense.
Robust risk disclosure protects the sponsor. The long, ugly list of everything that could go wrong, the honest statement that the market could turn, the reserve could run short, the refinance could fail, the investor could lose everything, is not a sales liability. It is the record that the sponsor told investors the truth about the risks. When a deal loses money and an investor sues, the question is whether they were told what they needed to know. The sponsor who disclosed the risk in plain language has an answer. The sponsor who buried or softened it to make the deal look safer has handed the plaintiff the case.
The structuring consequence
Build the disclosure to survive a lawsuit, not to win the raise. Say what can go wrong, clearly, and say it everywhere the deal is presented, because as the sponsor-representations and marketing pages show, anti-fraud reaches every channel, not just the PPM. The exemption work protects you from having to register. Only the disclosure work protects you from fraud liability, and no amount of the first substitutes for the second.